Medically assisted treatment, commonly called MAT, is the use of FDA-approved medications combined with counseling to treat substance use disorders, primarily opioid and alcohol addiction. It is considered the gold standard for opioid use disorder, with studies showing that treatment with medication reduces overdose risk by 76% within the first three months. Rather than requiring a person to quit through willpower alone, MAT stabilizes brain chemistry so recovery becomes possible.
How MAT Medications Work
Three medications are FDA-approved for opioid use disorder: methadone, buprenorphine, and naltrexone. Each works differently, and the choice depends on a person’s medical history, stage of recovery, and daily life.
Methadone is a full opioid agonist, meaning it activates the same brain receptors that heroin or prescription painkillers do, but in a slower, more controlled way. It prevents withdrawal symptoms and reduces cravings without producing the intense high of street opioids. Because it fully activates the receptor, it also creates a tolerance effect that blocks the euphoria from any opioids used on top of it. This “blockade” was first tested in the 1960s and remains one of the most effective tools for severe opioid addiction.
Buprenorphine is a partial agonist. It activates the same receptors but only partially, producing a ceiling effect: beyond a certain dose, its effects plateau. This makes it significantly safer in terms of overdose risk, particularly regarding the respiratory depression that makes opioid overdoses fatal. Buprenorphine comes in several forms, including dissolving films or tablets placed under the tongue and monthly injections. Many formulations combine buprenorphine with naloxone, which discourages misuse by triggering withdrawal if the medication is injected rather than taken as directed.
Naltrexone takes the opposite approach entirely. It’s an opioid antagonist, meaning it blocks the receptors without activating them at all. If someone on naltrexone uses opioids, they won’t feel the effects. It’s available as a daily pill or a monthly injection. The catch is that a person must be fully detoxed from opioids before starting naltrexone, which can be a significant barrier.
MAT for Alcohol Use Disorder
Naltrexone also works for alcohol addiction. Alcohol triggers the brain’s reward system partly through opioid receptors, and by blocking those receptors, naltrexone reduces the pleasurable effects of drinking and dampens cravings. People on naltrexone for alcohol use disorder often report that drinking simply feels less rewarding, making it easier to stop or cut back.
Two additional medications are approved specifically for alcohol use disorder. Acamprosate helps rebalance a brain signaling system that gets disrupted by chronic alcohol use, reducing the persistent discomfort and anxiety that drive people to relapse after they stop drinking. Disulfiram works through a completely different mechanism: it blocks the enzymes your body uses to break down alcohol, causing nausea, flushing, and vomiting if you drink. It’s essentially a deterrent rather than a craving reducer.
Where Treatment Happens
The logistics of MAT vary dramatically depending on the medication. Methadone can only be dispensed through specialized Opioid Treatment Programs (OTPs). These are regulated clinics where, especially early in treatment, patients visit daily to receive their dose under direct observation by a nurse or pharmacist. As a patient demonstrates stability, they can earn take-home doses and visit less frequently. OTPs are required to provide counseling, case management, and health education alongside medication.
Buprenorphine and naltrexone can be prescribed in a regular doctor’s office, a practice known as office-based opioid treatment. A provider writes a prescription, and you fill it at a pharmacy like any other medication. This model also works through telehealth platforms, meaning some patients can receive prescriptions without an in-person visit. Office-based treatment doesn’t require drug testing or a formal diversion control plan, and the provider isn’t obligated to offer counseling services, though many do or provide referrals.
A major regulatory change in 2023 made buprenorphine significantly easier to access. Previously, doctors needed a special federal waiver (called an X-waiver) to prescribe it. That requirement was permanently eliminated by the Consolidated Appropriations Act. Now any practitioner with a standard DEA registration can prescribe buprenorphine for opioid use disorder. State laws still vary, so access depends partly on where you live.
How Long Treatment Lasts
Clinical guidelines are clear on this point: MAT works best as long-term maintenance, often lasting years. Detoxification alone, without ongoing medication, consistently produces poor outcomes and high relapse rates. Many treatment programs don’t even offer a direct pathway from medication to a completely drug-free state because the relapse risk is so high.
When patients and providers do decide to taper off buprenorphine, the process is slow, typically stretching over several months. Clinical consensus holds that several conditions should be met before discontinuing: the patient wants to stop, has stable housing and income, and has adequate social support. If relapse occurs or risk is high, guidelines recommend restarting medication immediately rather than waiting.
For naltrexone, there’s no recommended fixed treatment length. Duration is determined by individual circumstances, making it a more flexible option for people whose recovery trajectory is harder to predict.
Evidence for Effectiveness
The data on MAT’s effectiveness is among the strongest in addiction medicine. A national study of over 40,800 people found that buprenorphine or methadone reduced overdose risk by 76% at three months and 59% at twelve months. The slight decrease over time reflects the reality that some people discontinue medication, but the protection remains substantial even at a year.
The evidence is especially striking for people leaving incarceration, a period of extreme overdose vulnerability because tolerance drops during imprisonment. Starting methadone or buprenorphine while still incarcerated reduced the risk of death by up to 75% within the first month after release. Rhode Island, the first state to offer all three MAT medications in its prison system, saw overdose deaths among formerly incarcerated people drop by 61% within a year.
Beyond survival, MAT improves treatment engagement. People who received medication while incarcerated were 60% more likely to start community treatment within 30 days of release, and 58% remained in treatment six months later. They also had a 12% lower risk of returning to prison.
Why MAT Isn’t “Replacing One Addiction With Another”
The most persistent criticism of MAT is that it substitutes one drug for another. This misunderstanding confuses physical dependence with addiction, two conditions that are medically distinct. Physical dependence means your body has adapted to a substance and will experience withdrawal if it’s stopped. This happens with many medications that have nothing to do with addiction, including certain antidepressants and blood pressure drugs. When people stop those medications, they may have withdrawal symptoms but don’t crave them or compulsively seek them out.
Addiction, by contrast, is the loss of control over drug use despite harmful consequences. It involves intense cravings and compulsive behavior. A person can be physically dependent without being addicted, and addicted without being physically dependent. Cocaine, for example, causes severe cravings and relapse but relatively few visible physical withdrawal symptoms.
Someone on a stable dose of methadone or buprenorphine is physically dependent on the medication, just as a person with diabetes is dependent on insulin. But they’re not experiencing the chaotic cycle of craving, intoxication, and withdrawal that defines addiction. They can hold jobs, maintain relationships, and function normally. The medication manages a chronic brain condition so that recovery is sustainable rather than a white-knuckle exercise in abstinence.